ArticleMolecular oncology2026
Epigenetics in cancer: from mechanisms to precision medicine.
Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Epigenetics encompasses heritable yet reversible changes in gene expression that occur without alterations to the underlying DNA sequence. Through coordinated regulation of DNA methylation, histone modifications, chromatin remodeling, and higher-order chromatin organization, epigenetic mechanisms shape chromatin accessibility and transcriptional programs that govern cellular identity, plasticity, and tissue homeostasis. In cancer, disruption of the epigenetic landscape has emerged as a hallmark of tumor initiation, progression, metastasis, immune evasion, and therapeutic resistance. Unlike genetic alterations, epigenetic abnormalities are potentially reversible, making them attractive therapeutic targets. Recent advances in next-generation sequencing, single-cell and spatial multi-omics, chromatin profiling technologies, and computational biology have transformed our understanding of cancer epigenomes while accelerating the development of epigenetic therapies targeting diverse chromatin regulatory pathways. This Thematic Issue on Epigenetics in Cancer brings together leading experts to review recent conceptual and technological advances that are reshaping the field. Covering topics ranging from spatial and single-cell epigenomics to chromatin regulation, tumor plasticity, and emerging therapeutic strategies, the collection highlights how fundamental discoveries are driving translational innovation and precision oncology. We hope these articles will provide a valuable resource for researchers and clinicians while inspiring future advances in cancer epigenetics and epigenetic therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.